Early Technology Showcase

Capital BioVentures is a not-for-profit wet-lab accelerator located in Ottawa that offers early-stage funding and resources to Canadian companies. The organization provides access to specialized drug and corporate development professionals, as well as high-quality laboratory space, equipment, and non-dilutive funding. Backed by investments from FedDev Ontario and the National Research Council’s Industrial Research Assistance Program, CBV provides full-service supports, allowing small- and medium-sized enterprises (SMEs) to develop their products and expand their businesses.

The McGill Dobson Centre for Entrepreneurship is McGill University’s hub for innovation and venture creation. We support a global community of 530+ start-ups that have raised $4.1B, hold 258 active patents, and created 12,000 jobs across 46 countries.

With over a third of our portfolio in life sciences, and the ranking of McGill amongst the best universities for medical research, we are proud to support some of the most cutting-edge discoveries in biotechnology, precision medicine, and medical devices as they commercialize nationally and internationally.

Recognized globally for our ecosystem, we are proud to count partnerships with Mass General Brigham, Hôtel-Dieu de Parie, and King’s College London.

The Stem Cell Network (SCN) is a mission-driven not-for-profit organization that unites researchers, clinicians, industry leaders, and health champions dedicated to transforming lives through regenerative medicine. As Canada’s only national organization with a specific focus on this field, SCN is uniquely positioned to drive progress in the fight against disease and power Canada’s economy through company creation and the development of future leaders.

For nearly 25 years, SCN has built a trusted, collaborative network that aligns researchers, clinicians and bioentrepreneurs across Canada and globally. Through a small but dedicated staff team and the support of expert volunteers, SCN effectively delivers research programs, mentors emerging talent, accelerates the development of cutting-edge therapies, and supports the growth of biotech companies across Canada.

Since its inception, SCN has invested over $162 million in Canadian regenerative medicine research, leveraging an additional $176 million from partners. This funding has positioned Canada as a global leader in regenerative medicine, fostering world-class expertise, spinning out innovative biotech companies, and pioneering life-changing clinical trials.